Novartis India Ltd
NSE:NOVARTIND

Watchlist Manager
Novartis India Ltd Logo
Novartis India Ltd
NSE:NOVARTIND
Watchlist
Price: 672.25 INR Market Closed
Market Cap: 16.6B INR

Novartis India Ltd
Accounts Payable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Novartis India Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Novartis India Ltd
NSE:NOVARTIND
Accounts Payable
₹435.7m
CAGR 3-Years
-7%
CAGR 5-Years
-13%
CAGR 10-Years
-9%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Accounts Payable
₹35.3B
CAGR 3-Years
20%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Accounts Payable
₹30.4B
CAGR 3-Years
8%
CAGR 5-Years
5%
CAGR 10-Years
6%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Accounts Payable
₹67.1B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
6%
Lupin Ltd
NSE:LUPIN
Accounts Payable
₹29.6B
CAGR 3-Years
10%
CAGR 5-Years
5%
CAGR 10-Years
4%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Accounts Payable
₹16.8B
CAGR 3-Years
4%
CAGR 5-Years
-6%
CAGR 10-Years
-3%
No Stocks Found

Novartis India Ltd
Glance View

Market Cap
16.6B INR
Industry
Pharmaceuticals

Novartis India Ltd. engages in developing and marketing transformative treatments for people in areas of medical need. The company is headquartered in Mumbai, Maharashtra and currently employs 81 full-time employees. The firm focuses on over three divisions, including pharmaceuticals, eye care and generic medicines. In India, its pharmaceutical business is focused on bone and pain, calcium portfolio, gynecology and neurosciences, and the generics business is focused on gynecology, anti-tuberculosis (TB) and anti-infectives. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolism, immunology and dermatology, ophthalmology, neuroscience and respiratory. The company develops gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The company is developing a chimeric antigen receptor (CAR)-T platform for various investigational CAR-T therapies in its pipeline. The firm has presence in various locations in India, including Delhi, Bengaluru, Kolkata, Chennai and Lucknow.

NOVARTIND Intrinsic Value
Not Available

See Also

What is Novartis India Ltd's Accounts Payable?
Accounts Payable
435.7m INR

Based on the financial report for Sep 30, 2023, Novartis India Ltd's Accounts Payable amounts to 435.7m INR.

What is Novartis India Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
-9%

Over the last year, the Accounts Payable growth was -22%. The average annual Accounts Payable growth rates for Novartis India Ltd have been -7% over the past three years , -13% over the past five years , and -9% over the past ten years .

Back to Top